Product Information
HYDROMORPHONE HCL ER 8 MG TAB is a generic product labeled by Camber Pharmaceuticals Inc., priced at $5.7288 per EA under NDC 31722011901. Its NADAC has been published 172 times since Jun 21, 2023.
FDA first approved this application on Sep 23, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722011901
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROMORPHONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212133FDA Approved
9/23/2020
TE Code
AB
On Market Since
9/24/2020
Pharmacological Classes
Price Statistics
The NADAC for HYDROMORPHONE HCL ER 8 MG TAB has been published 172 times since Jun 21, 2023, and over the history we have for it it has risen 75.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.7288 per EA |
|---|---|
| All-time high | $7.0165 (Apr 15, 2026) |
| All-time low | $3.0250 (Mar 20, 2024) |
| 52-week high | $7.0165 |
| 52-week low | $5.7288 |
| Median price | $4.7714 |
| Average price | $4.9106 |
| Largest weekly change | +45.8% (Oct 18, 2023) |
| Weeks tracked | 172 |
| Tracking since | Jun 21, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
hydromorphone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROMORPHONE HCL ER 8 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for HYDROMORPHONE HCL ER 8 MG TAB, manufactured by Camber Pharmaceuticals Inc., is $5.7288 per EA (NDC 31722011901), effective Sep 30, 2026.
How has the price of HYDROMORPHONE HCL ER 8 MG TAB changed over time?
Over the history we have for it, the NADAC for HYDROMORPHONE HCL ER 8 MG TAB has risen 75.1%. It has been tracked across 172 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for HYDROMORPHONE HCL ER 8 MG TAB?
Since Jun 21, 2023, the NADAC for HYDROMORPHONE HCL ER 8 MG TAB has ranged from a low of $3.0250 (Mar 20, 2024) to a high of $7.0165 (Apr 15, 2026), with a median of $4.7714 per EA.
Are there cheaper alternatives to HYDROMORPHONE HCL ER 8 MG TAB?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HYDROMORPHONE 8 MG TABLET, is $0.5609 per EA — about 90% below HYDROMORPHONE HCL ER 8 MG TAB.
Who manufactures HYDROMORPHONE HCL ER 8 MG TAB?
HYDROMORPHONE HCL ER 8 MG TAB (NDC 31722011901) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.